3.96
Schlusskurs vom Vortag:
$3.95
Offen:
$3.95
24-Stunden-Volumen:
1.99M
Relative Volume:
1.11
Marktkapitalisierung:
$255.66M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-71.17M
KGV:
-2.8489
EPS:
-1.39
Netto-Cashflow:
$-70.97M
1W Leistung:
+178.87%
1M Leistung:
+284.47%
6M Leistung:
+40.93%
1J Leistung:
-15.38%
Inozyme Pharma Inc Stock (INZY) Company Profile
Firmenname
Inozyme Pharma Inc
Sektor
Branche
Telefon
857-330-4340
Adresse
321 SUMMER STREET, BOSTON
Vergleichen Sie INZY mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
INZY
Inozyme Pharma Inc
|
3.96 | 91.68M | 0 | -71.17M | -70.97M | -1.39 |
![]()
ONC
Beigene Ltd Adr
|
238.76 | 24.41B | 3.81B | -644.79M | -669.77M | -6.24 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
434.03 | 111.55B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
AKTX
Akari Therapeutics Plc Adr
|
1.2548 | 42.47M | 0 | 0 | 0 | 0.00 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
596.85 | 63.16B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
VRNA
Verona Pharma Plc Adr
|
72.69 | 5.92B | 0 | -153.72M | -103.81M | -2.00 |
Inozyme Pharma Inc Stock (INZY) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2024-12-12 | Eingeleitet | Raymond James | Outperform |
2024-09-12 | Eingeleitet | Stifel | Buy |
2024-08-13 | Fortgesetzt | Jefferies | Buy |
2024-05-30 | Eingeleitet | Wells Fargo | Overweight |
2023-03-23 | Hochstufung | Jefferies | Hold → Buy |
2022-05-26 | Eingeleitet | Jefferies | Hold |
2022-02-07 | Eingeleitet | H.C. Wainwright | Buy |
2021-11-29 | Eingeleitet | Needham | Buy |
2020-08-18 | Eingeleitet | BofA Securities | Buy |
2020-08-18 | Eingeleitet | Cowen | Outperform |
2020-08-18 | Eingeleitet | Piper Sandler | Overweight |
2020-08-18 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Inozyme Pharma Inc Aktie (INZY) Neueste Nachrichten
Biotech Stock Roundup: BMRN to Acquire INZY, NVAX Gains on Vaccine Approval & More - Zacks Investment Research
BioMarin Offers to Buy Inozyme for $270M to Boost Enzyme Therapy Biz - MSN
BioMarin’s Acquisition of Inozyme Pharma - Global Legal Chronicle
INOZYME PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inozyme Pharma, Inc.INZY - Business Wire
BioMarin agrees to acquire Inozyme for $270m - MSN
Biotech Alert: Searches spiking for these stocks today - Yahoo Finance
Inozyme Stock Rockets 179% After BioMarin Agrees To Acquire The Company For $270M: Retail Sentiment Brightens - MSN
BioMarin Expands Rare Disease Portfolio with $270M Inozyme Acquisition - MSN
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
Inozyme Pharma finds buyer in BioMarin after strategic review - The Business Journals
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Inozyme Pharma, Inc. (Nasdaq – INZY), TXNM Energy, Inc. (NYSETXNM), Servotronics, Inc. (NYSE AmericanSVT), Protagenic Therapeutics, Inc. (Nasdaq – - TradingView
BioMarin: Inozyme Acquisition Falls Short Of Offsetting Looming Revenue Risks (Downgrade) - Seeking Alpha
Piper Sandler Downgrades Inozyme Pharma to Neutral From Overweight, Lowers Price Target to $4 From $23 - marketscreener.com
TD Cowen Downgrades Inozyme Pharma to Hold From Buy, Price Target is $4 - marketscreener.com
Raymond James Downgrades Inozyme Pharma to Market Perform From Outperform - marketscreener.com
BioMarin to acquire Inozyme to enhance its enzyme therapy portfolio - World Pharmaceutical Frontiers
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SWTX, NVEE, CHTR, INZY on Behalf of Shareholders - GlobeNewswire Inc.
BioMarin Buying Inozyme Pharma In $270 Million Deal - Pulse 2.0
StockWatch: With Inozyme Buyout, BioMarin Pursues Growth via M&A - Genetic Engineering and Biotechnology News
The week in pharma: action, reaction and insight – week to May 16 - The Pharma Letter
Wells Fargo & Company Reaffirms Equal Weight Rating for Inozyme Pharma (NASDAQ:INZY) - Defense World
Inozyme Pharma (NASDAQ:INZY) Stock Rating Lowered by Wedbush - Defense World
Inozyme Pharma (NASDAQ:INZY) Earns Hold Rating from Jefferies Financial Group - Defense World
BioMarin to buy enzyme therapy developer Inozyme in $270M all-cash deal - MSN
Leerink bullish on BioMarin following Inozyme deal, expects additional BD - Yahoo Finance
Wedbush Has Negative Outlook for Inozyme Pharma Q2 Earnings - Defense World
Inozyme Pharma (INZY) Downgraded by Needham Analyst | INZY Stock News - GuruFocus
Inozyme downgraded to Hold from Buy at TD Cowen - TipRanks
BioMarin to acquire Inozyme for $270 million By Investing.com - Investing.com South Africa
Inozyme Pharma (INZY) Downgraded by Wells Fargo | INZY Stock New - GuruFocus
BioMarin’s $270m Inozyme Buy Fits Right Into Enzyme Therapy Business - insights.citeline.com
Inozyme Pharma (INZY) Downgraded by Wells Fargo | INZY Stock News - GuruFocus
Inozyme stock rating cut to Hold at Jefferies, target to $4 from $15 - Investing.com Nigeria
Inozyme stock rating cut to Hold at Jefferies, target to $4 from $15 By Investing.com - Investing.com South Africa
Inozyme (INZY) Downgraded Following Acquisition Deal | INZY Stoc - GuruFocus
TD Cowen cuts Inozyme stock rating post-acquisition news - Investing.com Australia
TD Cowen cuts Inozyme stock rating post-acquisition news By Investing.com - Investing.com Nigeria
Biomarin snags potential ‘first-in-disease’ ERT in $270M Inozyme buy - BioWorld MedTech
BioMarin’s $270M Inozyme Acquisition Brings Drug That Could Become First for a Rare Disease - MedCity News
Inozyme Pharma (INZY) Sees Price Target Slash and Downgrade by J - GuruFocus
Inozyme Pharma’s Strategic Acquisition by Biomarin: Analyst Holds Rating Amid Favorable Shareholder Outcome and Strategic Alignment - TipRanks
Inozyme (INZY) Downgraded Following Acquisition by BioMarin | INZY Stock News - GuruFocus
Dollar Stock Skyrockets 179% On BioMarin Takeover - Investor's Business Daily
BioMarin stock rises following Inozyme Pharma acquisition By Investing.com - Investing.com Nigeria
BioMarin stock rises following Inozyme Pharma acquisition - Investing.com Australia
BioMarin to acquire Inozyme for $4.00 per share in cash, or $270M - TipRanks
Jefferies Downgrades Inozyme Pharma to Neutral From Buy - marketscreener.com
BioMarin Pharmaceutical: Balancing Opportunities and Risks Amid Inozyme Acquisition and Market Challenges - TipRanks
Jefferies Downgrades Inozyme (INZY) After Acquisition Announceme - GuruFocus
Jefferies Downgrades Inozyme (INZY) After Acquisition Announcement | INZY Stock News - GuruFocus
Inozyme downgraded to Hold from Buy at Jefferies - TipRanks
Finanzdaten der Inozyme Pharma Inc-Aktie (INZY)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):